![]() ![]() The device has a high safety profile including a low risk of distal embolization.Īspiration Calcified lesions Denovo disease Distal embolization In-stent restenosis Laser Peripheral arterial disease Restenosis Solid-state laser.Ĭopyright © 2018 Elsevier Inc. ![]() The Eximo B-Laser™ is effective and safe in ablating atherosclerotic and restenotic tissue for both above and below the knee obstructive arterial disease. There was no target lesion revascularization and the patency was 96.8% by duplex ultrasound criteria at 30-day follow up. A significant improvement from baseline in ABI (0.24 ± 0.18), Rutherford category (-1.79 ± 1.22) and WIQ (0.26 ± 0.28) were noted at 1 month. Per Core lab, there was no device-related distal embolization, dissections that required additional therapy, perforation, or pseudoaneurysm. The freedom from MAE through the 30-day follow-up period after intervention was 98.9%. This resulted in a mean reduction from baseline to post B-Laser™ of 33.6% ± 14.2% meeting the primary efficacy endpoint goal. Post B-Laser™ and prior to adjunctive therapy, the mean percent stenosis at the target lesion was 52.1%. The mean percent stenosis at the target lesion as assessed by the Core lab was 85.7% ± 12.2 (femoro-popliteal 85.6 ± 12.8% tibials 86.0 ± 9.6%). Lesions were de novo (79.4%), followed by in-stent restenosis (ISR) (15.9%) and non in-stent restenosis (4.7%). Mean lesion length was 53.96 ± 43.18 mm and 26.2% had severe calcification. Mean age was 70.5 years and 51% were males. The primary safety endpoint was freedom from major adverse events (MAEs) defined as: unplanned target limb amputation above the ankle, clinically driven target lesion revascularization (CD-TLR) and cardiovascular related death.Ī total of 97 subjects (107 lesions) were enrolled. The primary efficacy endpoint was the average reduction in residual diameter stenosis of >20% from baseline prior to any adjunctive therapy achieved by the B-Laser™ catheter alone. The study enrolled patients in the United States and Europe. pivotal trial of the EXIMO B-Laser™.ĮX-PAD-03 is a prospective, single-arm, multi-center, international, open-label, clinical study. We present the results of the EX-PAD-03 U.S. Early data showed that the B-Laser™ is safe in treating a broad range of infrainguinal arterial lesions. The data presented on this page does not represent the view of Eximo and its employees or that of Zippia.Įximo may also be known as or be related to EXIMO, LLC, Eximo and Eximo Inc.B-Laser™ is a novel atherectomy device that uses a solid-state third harmonic pulsed Nd:YAG laser with an output of 355 nm. None of the information on this page has been provided or approved by Eximo. Eximo safely treats plants suffering from high. Regular use will also lower soil bicarbonate levels and improve soil structure. Eximo is designed to be sprayed directly onto turf to solubilize calcium and other salts. ![]() While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. Eximo is a state of the art acid replacement soil conditioner powered by SynTech, the world’s only synthetic acid. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. ![]() The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. The employee data is based on information from people who have self-reported their past or current employments at Eximo. Zippia gives an in-depth look into the details of Eximo, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Eximo. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |